tafamidis

all catalysts(0)

nothing on the calendar yet

News(10)

• ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy
  At a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors while a failed study pressured Alnylam.
  biopharma_dive · 1mo ago
• ESC: Alnylam's next-gen silencer sees silver linings after fallout of AZ, Ionis trial in ATTR-CM
  As AstraZeneca appears to close the book on a combo approach following the phase 3 failure of its Ionis-partnered Wainua, several analysts contend it’s too early to count out Alnylam’s silencing dr…
  fiercebiotech · 1mo ago
• ‘Worse than expected’ Wainua data muddies water for TTR silencers
  AstraZeneca and Ionis Pharmaceuticals’ data drop divulging more details from its highly watched Phase 3 transthyretin silencer trial “further confuses the picture” for Wainua when combined with the…
  biospace · 1mo ago
• AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease
  Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for TTR cardiomyopathy and amplified investor pressure on Alnylam.
  biopharma_dive · 1mo ago
• BridgeBio continues ATTR ascent as Alnylam’s Amvuttra falls short of expectations
  BridgeBio Pharma’s transthyretin amyloidosis medicine Attruby is off to a strong launch, while Alnylam lowered full-year sales guidance for competitor Amvuttra.
  biospace · 1mo ago
• Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
  Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.
  biopharma_dive · 2mo ago
• Pfizer expands multibillion-dollar cost-cutting plan
  Hatched three years ago, the restructuring is now expected to deliver $1 billion in new cost reductions and save Pfizer another $1.5 billion by streamlining drug production.
  biopharma_dive · 2mo ago
• 5 companies advancing ATTR assets in the wake of Wainua’s fail
  The Phase 3 failure of AstraZeneca and Ionis Pharmaceuticals’ antisense therapy in transthyretin amyloid cardiomyopathy last month left the space reeling—and readjusting. BioSpace looks at five con…
  biospace · 2mo ago
• Alnylam plunges as earnings deliver ‘one-two punch’
  The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.
  biopharma_dive · 2mo ago
• Biotechs bring big launches and pharma rivalries into Q2 earnings period
  With the second quarter earnings period underway, BioSpace examines five biotechs with meaningful catalysts that analysts and investors are watching.
  biospace · 2mo ago